GlaxoSmithKline plc (LON:GSK)‘s stock had its “neutral” rating reiterated by equities research analysts at JPMorgan Chase & Co. in a research note issued on Thursday.

A number of other equities analysts have also weighed in on the company. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, July 27th. BNP Paribas restated a “neutral” rating and issued a GBX 1,430 ($18.67) target price on shares of GlaxoSmithKline plc in a research report on Sunday, July 3rd. Goldman Sachs Group Inc. restated a “buy” rating and issued a GBX 1,800 ($23.50) target price on shares of GlaxoSmithKline plc in a research report on Tuesday, July 12th. Citigroup Inc. restated a “buy” rating on shares of GlaxoSmithKline plc in a research report on Thursday, June 23rd. Finally, Morgan Stanley lifted their target price on GlaxoSmithKline plc from GBX 1,500 ($19.58) to GBX 1,650 ($21.54) and gave the company an “equal weight” rating in a research report on Monday, July 11th. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of GBX 1,676.44 ($21.88).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1629.50 on Thursday. GlaxoSmithKline plc has a 12 month low of GBX 1,227.50 and a 12 month high of GBX 1,716.50. The company’s 50-day moving average price is GBX 1,654.01 and its 200-day moving average price is GBX 1,531.21. The company’s market cap is GBX 79.21 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/glaxosmithkline-plc-gsk-stock-rating-reaffirmed-by-jpmorgan-chase-co-2.html

The business also recently disclosed a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be given a dividend of GBX 19 ($0.25) per share. The ex-dividend date of this dividend is Thursday, August 11th. This represents a yield of 1.12%.

In other news, insider Witty,Sir Andrew P sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total transaction of £169,300 ($220,989.43). Also, insider Slaoui,Moncef bought 28 shares of the business’s stock in a transaction dated Friday, August 12th. The shares were acquired at an average cost of GBX 2,208 ($28.82) per share, with a total value of £618.24 ($807.00).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.